Citius Pharmaceuticals, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported net loss was USD 32.54 million compared to USD 33.64 million a year ago. Basic loss per share from continuing operations was USD 0.22 compared to USD 0.23 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.6648 USD | -9.25% | -11.88% | -12.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.12% | 120M | |
+1.51% | 42.75B | |
+48.20% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- CTXR Stock
- News Citius Pharmaceuticals, Inc.
- Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023